RTsafe welcomes Dr Penny Kechagioglou to its Board of Directors

Athens, Greece , May 12, 2026 — RTsafe is pleased to announce the appointment of  Dr Penny Kechagioglou to its Board of Directors, marking an important addition to the company’s leadership as it enters a new phase of international growth, clinical service expansion, and strategic development.

Dr Kechagioglou is a highly respected Clinical Oncologist and senior healthcare leader with an outstanding career across oncology, clinical leadership, healthcare innovation, digital transformation, governance, and integrated cancer care. She currently serves as Chief Medical Officer for Icon UK and practises as a Consultant Clinical Oncologist at University Hospitals Coventry and Warwickshire. Her career has included senior leadership roles across the UK NHS, private healthcare, and charitable organisations, with a strong focus on patient-centred care, clinical governance, organisational transformation, and the future of cancer treatment.

Her appointment comes at a pivotal time for RTsafe. In 2026, the company is expanding its production capabilities, entering new international markets — with particular momentum in the Middle East — and developing new Clinical Audit Services to further support quality, safety, and confidence in radiation oncology.

Dr Kechagioglou’s deep clinical expertise, international leadership experience, and passion for innovation in cancer care will bring significant value to RTsafe’s Board as the company continues to grow its impact globally.

“It is a true pleasure to welcome Penny to the RTsafe Board,” said Evangelos Pappas, Founder and CSO of RTsafe. “Penny brings a rare combination of clinical excellence, strategic thinking, leadership, and humanity. She creates real impact in everything she does. I am deeply confident that her contribution to RTsafe will be significant, especially as we continue to grow internationally and strengthen our role in supporting safe, high-quality radiation oncology.”

Dr Kechagioglou brings a diverse and impressive background to RTsafe. Her experience spans advanced radiotherapy, breast cancer care, personalised oncology, immunotherapy, integrative oncology, digital health, healthcare leadership, clinical strategy, research, and innovation. She has also contributed to healthcare thought leadership through publications, speaking engagements, advisory roles, and board-level appointments.

“I am delighted to join the Board of RTsafe at such an exciting moment in the company’s journey,” said Dr Penny Kechagioglou. “RTsafe’s mission is closely aligned with what I believe is essential in modern cancer care: safety, precision, innovation, and a deep commitment to patients and clinical teams. I look forward to contributing my experience in oncology, healthcare leadership, and service transformation to support RTsafe’s continued growth and its impact in radiation oncology worldwide.”

RTsafe’s Board brings together expertise from medical physics, oncology, business, investment, legal strategy, marketing and communications, and healthcare leadership. With Dr Kechagioglou joining the Board, RTsafe further strengthens its clinical and strategic perspective at a time of major opportunity.

Dr Kechagioglou’s appointment reflects RTsafe’s continued commitment to bringing together world-class expertise in support of safer, smarter, and more patient-centred radiation oncology.

Press to download the Press Release

For media inquiries, please contact: Ms. Marianna Liondou, [email protected]

About RTsafe

RTsafe is a medical technology company committed to improving the safety and effectiveness of radiotherapy worldwide. Through patient-specific 3D dosimetry, anthropomorphic phantoms, and independent auditing services, RTsafe supports clinics in optimizing treatment accuracy and enhancing patient outcomes. Learn more atwww.rt-safe.com.